The recent results of VERTIS-CV have provided new insights into the individual and class effects of SGLT2 inhibitors, prompting further considerations of the multifactorial effects of these medications. But what made this trial so thought-provoking?

This week, join us for a retrospective review of outcomes trials for SGLT2 inhibitors and a detailed discussion of the VERTIS-CV trial with Dr Chris Cannon, cardiologist at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and principal investigator for the VERTIS-CV trial.

References

This independent educational activity is supported by an educational grant from Merck Sharp & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Merck Sharp & Dohme Corp has had no influence on the content of this education.

A series of expert interviews conducted at ADA 2020. This includes:

Professor Tina Vilsboll

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education

Over the first half of the year, we've taken an in-depth look at guideline algorithms, best practice recommendations and expert advice on optimising outcomes in the earlier stages of type 2 diabetes. 

To help summarise all this guidance and put it into perspective, join Professor Peter Rossing of the Steno Diabetes Centre Copenhagen for a discussion of three model patient cases.

This independent educational activity is supported by an educational grant from Merck Sharp & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Merck Sharp & Dohme Corp has had no influence on the content of this education.

Guidelines recommend normalisation of body weight, but how are we able to assist people with diabetes in achieving this? Join Professor Carel le Roux for a detailed discussion of optimal approaches in obesity management.

References

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Join Professor Steve Bain for a discussion of common side effects across commonly-used antihyperglycaemic agents, including metformin, SGLT2 inhibitors, DPP-4 inhibitors and GLP-1 receptor agonists.

References

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

At the start of 2020, new guidelines were published by the EASD and ADA providing new recommendations on treatment escalation. But how should we implement these into practice?

Join Dr Ronald Goldenberg from LMC Diabetes & Endocrinology in Thornhill, Canada for a summary of guideline advice and how it applies in daily practice

References

Consentino, et al. Eur Heart J 2020; 2(7):255-323

Buse JB, et al. Diabetes Care. 2020 Feb;43(2):487-493.

American Diabetes Association. Diabetes Care  2020; 42(suppl1)

This independent educational activity is supported by an educational grant from Merck Sharp & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Merck Sharp & Dohme Corp has had no influence on the content of this education.

A mountain of data exist for each antihyperglycaemic agent, from metformin through to the most recently   approved agent. Considering all these data, what are the most significant   observations to date?

Join Professor Jens Juul Holst from the   University of Copenhagen for a summary of data on DPP-4 inhibitors, SGLT2   inhibitors and GLP-1 receptor agonists, including a particular focus on   within-class differences and whether oral vs injectable formulations have   different effects

References

- Pinto LC, et al. Diabetol Metab Syndr. 2015; 7(Suppl 1): A58

- Craddy P, et al. Diabetes Ther. 2014;5(1):1-41.

- Uccellatore A, et al. Diabetes Ther. 2015;6(3):239-56

- Nauck MA, et al. Diabetologia. 2016; 59(2):266-74.

- Aroda VR, et al. Diabetes Obes Metab. 2020; 22(3):303-314

- Ahrén B. Front Endocrinol (Lausanne). 2019;10:376 

- Rosenstock J, et al. JAMA. 2019 Sep 19. [Epub ahead of print]

- Kristensen SL. Lancet Diabetes Endocrinol. 2019; 7(10):776-785

- Romera I, et al. Diabetes Therapy 2019;   10:5-19

- McMurray JJV, et al. N Engl J Med 2019;   381:1995-2008

- Perkovic V, et al. N Engl J Med 2019;   380:2295-2306

- Fitchett D, et al. Diabetes Obes Metab. 2019;21   Suppl 2:34-42.

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

While it’s all very well and good to discuss optimal  treatment approaches in diabetes, it is imperative to involve patients themselves in treatment decisions and management approaches in diabetes. Join patient advocate Mr Ken Tait for a discussion of how to empower people with diabetes to optimise their self-care, and approaches to involving them in treatment decisions.

References

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Join Dr Kevin Fernando for a detailed discussion of how to implement recent guideline recommendations into daily clinical practice, including 2019 ESC recommendations and the 2020 EASD/ADA update.

References

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

All guidelines advocate for lifestyle interventions in the management of diabetes, including exercise, healthy eating and weight normalisation. But how can we actually help patients achieve this? Join us this week for a discussion of practical tips to achieve a healthy lifestyle, with expert advice from Professor Naveed Sattar. 

References

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.